From comparison of the post-NAC changes in sTILs, CD8+ T cells, CD4+ T cells, FOXP3+ Tregs, PD-L1 expression, MVD, and MPI between BC patients in the pCR and Non-pCR groups, the percentage of patients with enhanced sTILs, CD8+ T cells, and CD4+ T cells infiltration in the pCR group was found to be significantly higher than that in the Non-pCR group (P < 0.05), while the percentage of patients with reduced FOXP3+ Tregs in the pCR group was significantly higher than that in the Non-pCR group (P = 0.000) (Table 3). This evidence concerns the gene CD4 and breast cancer.